



Biosimilar medicines: Changing Patient Care Pathways, Changing Outcomes

For more than 15 years, biosimilar medicines in Europe have contributed to make biologic standards of care in Non-Communicable Diseases (NCDs) more accessible for more patients who needed them, while lowering treatment costs for healthcare system.

Political ambition and targets have been set in the UN Sustainable Development Goals for 2030, yet it is up to individuals, organisations and policy makers to take concrete actions to deliver better access, timely access and sometimes earlier access to medicines. Beyond the treatment and medicines pillar of NCD care, examples of reinvestments in hiring staff or deploying broader access to diagnostics is changing the quality of care. These investments are made possible with the smart use of biosimilar medicines.

In this online session, we would like to discuss European initiatives offering an opportunity to effectively deliver better care & outcomes, notably the revision of the **EU pharmaceutical legislation** and the development of the **European Healthier Together Initiative**. Presentations of concrete examples and experiences having delivered more value for health thanks to biosimilar medicines will allow for a debate on key features and enablers to be considered in advancing public health and biosimilar policies.

We invite you to join us on 28 April 2022 – 11am -12.30pm CEST

How can we deliver more care with the healthcare resources we already have available? What stands in the way of virtuous re-investments (from biosimilar medicines use) along the Non-Communicable Diseases care continuum?

Moderator: Suzanne Wait, The Health Policy Partnership (HPP)

SPEAKERS:

- **Iveta Nagyova, President, European Public Health Association (EUPHA)**
- **Nadia Amer, Health Economics Analyst, Health Product Department, Caisse Nationale d'Assurance Maladie (CNAM), France**
- **Silvio Danese, Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele Milan, Italy**
- **Xavier Mesrobian, Vice-Chair of the Biosimilar Medicines Market Access Committee, Biosimilar medicines group & Accord Healthcare**

The discussion is set to continue at the Biosimilar Medicines Conference (BIOS22) set to take place in Brussels, Belgium, on 6&7 October 2022. More information will be available soon.

For further information and to register for this online session

<https://www.medicinesforeurope.com/events/bios22live/>